The Challenges of Precision Medicine and New Advances in Molecular Diagnostic Testing in Hematolymphoid Malignancies: Impact on the VHA.

Jessica Wang‐Rodriguez(University of California San Diego), Claudio A. Mosse(Breast Cancer Research Foundation), Kim As(VA Greater Los Angeles Healthcare System), Michael Icardi(University of Iowa), F Baddoura(VA Greater Los Angeles Healthcare System), Ning Ma(Nanjing Forestry University), Steven A. Schichman(Central Arkansas Veterans Healthcare System), Lu Cm(VA Greater Los Angeles Healthcare System), Andrea Yunes(VA Greater Los Angeles Healthcare System), Ryan Phan(VA Greater Los Angeles Healthcare System)
PubMed
August 1, 2017
Cited by 2

Related Papers

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
|JAMA|2022|195
Long noncoding RNA H19 indicates a poor prognosis of colorectal cancer and promotes tumor growth by recruiting and binding to eIF4A3
|Oncotarget|2016|193
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
|Blood|2001|188
Accelerated DNA methylation age: Associations with PTSD and neural integrity
|Psychoneuroendocrinology|2015|152